Rischio e Prevenzione (Risk and Prevention) is a research project that is becoming the paradigm of the Italian research on General Practice. It started from a survey showing that treatment and control of cardiovascular risk is still far from optimal even in very high-risk patients. A group of general practitioners, coordinated by Istituto Mario Negri, wrote the protocol of the study with various proposals: Creating a research network. Building research infrastructure with good research capacity. Building a 'therapeutic alliance' with the patient while presenting the research, not only obtaining their signature for a 'bureaucratic' informed consent. Having the 'Collaborative Group' as the 'sponsor' of a research even if the funds are coming from Pharmaceutical Industry. It is a randomised controlled trial (RCT) carried out in primary care with the normal patient of our daily work, so transferability is very possible. The way to enrol the patients and the request to specify the reason for not joining the project of the outcome study are a kind of participatory research. The outcome study can become a model for implementing new strategy on cardiovascular risk. A specific questionnaire will enquire the different point of view of the patient and of the general practitioner/researcher. The result of this project will help us understand the phenomenon of the poor compliance of the high-risk patients. First results during enrolment allow some optimism.
Introduction
Risk and Prevention is a project that is becoming the paradigm of the research of Italian General Practice. Some aspects of this protocol are particularly original, according to the history of the Italian research, and the aim of this paper is to summarise all the multiple meanings.
R&P, Rischio e Prevenzione
It is a project coming from an epidemiological survey (Risk & Prevention, 2002) run by 166 Italian GPs in the 2000, where treatment and control of cardiovascular (c.v.) risk resulted still far from optimal even in very high-risk patients. This was a common result in the treatment of hypertension, diabetes, hyperlipaemia, and antiplatelet therapy.
The overall aim of this project is indeed to optimise the treatment of cardiovascular risk patients in daily practice.
A Collaborative Group from different scientific society of general practice and a pharmacological research institute designed the protocol of the study.
It is directed to high cardiovascular risk patients enrolled in the practice and it is divided into two parts: 1. The first part is an outcome study. The objective is to optimise the evidence-based preventive strategy. The approach on c.v. risk reduction is decided with an open discussion with the patient, analysing his personal situation, and sharing the decision on which c.v. risk will be faced in the first year. A form is filled where the decisions on control of BP, cholesterol level, body weight reduction, daily activity, and smoke habit are recorded.
Other possible interventions are admitted, and particular interest is paid to the reason for refusal of the proposal, and after 1 y, a second form will monitor the result of this intervention. 2. The second part is a double-blind RCT for evaluating the efficacy of the fish oil in high c.v. risk patients. End points of the study are the reduction in mortality, cardiovascular mortality, coronary death and sudden death, and nonfatal myocardial infarcts. This needs a large number of patients: to demonstrate a reduction on sudden death of 40%, a sample of 12 000 people is needed with a followup of 5 y. Foreseen target was to enrol 600 GPs (20 patients per GP).
Multiple meaning of R&P
There are at least eight different aspects to underline in this project: It is an experience that everyone hopes will continue in the future and may be the basis for a research infrastructure. (2) To become part of the research, each GP should participate in a specific course that includes research technology and communication skill. Informed consensus is a principal point of the course. The construction of research capability among Italian GPs is the second difficult task to be achieved and, although sometimes we face GPs without any experience on it, the courses already carried out allow some kind of optimism. (3) Informed consent should never be a bureaucratic act, but in this project, the collaboration of the patient is required in order to reach a sharing of the goal. Asking informed consent (a really informed consent) for the research is necessary, but is not enough. The objective of this research is to build a therapeutic alliance for the reduction of c.v. risk both using drugs, which represent a grey area in the primary prevention, and modifying the unhealthy habits with the collaboration of the patient. Particular attention has been paid to explaining to the patient the scope of this research and a consensus should also be reached for reducing the cardiovascular risk. A common strategy is needed for planning the reduction of cardiovascular risk. (4) The fourth point is related with the selection of the sample. Old patients and women, for example, are usually excluded by the criteria of the randomised controlled trials (RCTs). In daily activity though, they are the real patients that GPs deal with. Only if the project is perceived as a way to solve an ethical dilemma will these kinds of patients agree to be involved, and the results are expected to have a good transferability. In all, 80% of the people interviewed declared that they will agree to be part of another research project and that they understood the meaning of being randomised. R&P is also becoming an example of participatory research. Del Zotti, following the experience of Caimi and the researches performed by Julian Tudor Hart, has started his enrolment, inviting groups of patients in his waiting room, and discussing, all together, the strategy for the risk reduction during the research. (7) Beside the expected results on Omega 3 fatty acids and the outcome in c.v. risk reduction, a different approach towards high-risk patients is expected.
There is a clear feeling that doing research is improving clinical practice; and this kind of research may influence positively the relationship between GP and patients. (8) In order to describe the impact in daily activity of this research, three other forms has been added to investigate: (a) the curious, interesting point that impressed the doctor when he introduced the study to the patient; (b) the reason of refusal to enter the research (both filled by the doctor); and (c) how the research has been presented, possible problems arising to the doctor and the patient in this phase (filled by the patient). (9) This will be the basis for a qualitative study for understanding the different point of view of the patient and of the GP, and will inform how the research may influence the normal practice and the reasons for the refusal of the patient.
(Optimistic) conclusions
To date R&P is still enrolling GPs. The beginning has been difficult: the new law on research was a bureaucratic trouble: some Italian Regions do not allow GPs to do research without a special license delivered in the region, and some region have not yet started to organise the courses for researchers; again, every single local health unity must approve the protocol by the local Ethical Committee, and the total amount is over 100. Until now, all the Ethical committees have approved R&P, but it is still a long process to go. On the other hand, when in 2002 the Collaborative Group asked for 600 GPs working for 5 y some doubt arised, but the response of the researchers was exciting: 1300 GPs agreed to become part of this project, and in spite of all the bureaucratic troubles from January to December 2004, R&P has begun in 23 Local Health Unity and 319 have enrolled 4310 patients.
These numbers allow some optimism, and the hope to reach all the different goals of this research project seems to become real.
Discussion after Visentin
Green: I think this is a very exciting development for Italy and for Europe. Because your part of Europe has been relatively under-represented in this kind of research. And this is the very kind of research that I think is needed, more than additional RCTs. I think if we want more evidencebased practice, we have got to have more practice-based evidence. That is to say, we need more evidence that comes directly out of real practice situations. So my compliments to you.
Rosser: I would like to echo what Green said. The first study (aspirin) in this network has changed my way of looking at every study; I usually look at a study and say: that is not generalisable to my practice; but the way you carried out this study is generalisable to almost every practice in the world. Apart from this compliment, I have a question. I am very interested in your building research capacity, and would like to know more about the training. You talk about educating those 1300 physicians and they are going to learn more about research. What kind of programme do you have for that?
Visentin: It is now law in Italy that if you are part of a research programme you need to spend at least 8 h training for this specific research. And the other point is that the sponsoring pharmaceutical companies are granting the money, not doing anything in the research. The other point is that in these 8 h you just train people about what is a RCT. We do some role-play, comment, and discussions and so on. When you start doing research and when you have this kind of number of GPs, the research is going to grow.
Truswell: You mentioned a problem that we should not let go past, and that is the tremendous number of local Ethics Committees, which have to agree in Italy, and I wonder if this was in another country, how many Ethics Committees would GPs have to deal with? Because this is the first time, I have heard this as a barrier to the work of GPs.
Rosser: It would certainly be a quite lot in Canada.
Van Weel: In the Netherlands, it would be one.
